Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM: Results of two multicenter, randomized, placebo-controlled clinical trials

Diabetes Care

Volumn 20, Issue 4, 1997, Pages 597-606

  Simonson, Donald C ^a   Kourides, Ione A ^b   Feinglos, Mark ^c   Shamoon, Harry ^d   Fischette, Christine T ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b PFIZER INC   (United States)

^c DUKE UNIVERSITY   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIPIZIDE;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INSULIN RELEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

EID: 0030945291     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.20.4.597     Document Type: Article

References (62)

1. DeFronzo RA, Bonadonna RC, Ferrannini E: Pathogenesis of NIDDM. Diabetes Care 15:318-368, 1992
2. Yki-Järvinen H: Pathogenesis of noninsulin-dependent diabetes mellitus. Lancet 343:91-95, 1994
3. Reaven GM: Effect of glipizide treatment on various aspects of glucose, insulin, and lipid metabolism in patients with noninsulin-dependent diabetes mellitus. Am J Med 75 (Suppl. 5B):8-14, 1983
4. Feinglos MN, Lebovitz HE: Long-term safety and efficacy of glipizide. Am J Med 75 (Suppl. 5B):60-66, 1983
5. Lebovitz HE: Clinical utility of oral hypoglycemic agents in the management of patients with noninsulin-dependent diabetes mellitus. Am J Med 75 (Suppl. 5B):94-99, 1983
6. Gerich JE: Oral hypoglycemic agents. N Engl J Med 321:1231-1245, 1989
7. Kennedy DL, Piper JM, Baum C: Trends in use of oral hypoglycemia agents 1964-1986. Diabetes Care 11:558-562, 1988
8. Greenfield MS, Doberne L, Rosenthal M, Schulz B, Widstrom A, Reaven GM: Effect of sulfonylurea treatment on in vivo insulin secretion and action in patients with noninsulin-dependent diabetes mellitus. Diabetes 31:307-312, 1982
9. Pfeifer MA, Halter JB, Judzewitsch RG, Beard JC, Best JD, Ward WK, Porte D Jr: Acute and chronic effects of sulfonylurea drugs on pancreatic islet function in man. Diabetes Care 7 (Suppl. 1):25-34, 1984
10. Groop LC, Ratheiser K, Luzi L, Melander A, Simonson DC, Petrides A, Bonadonna RC, Widén E, DeFronzo RA: Effect of sulfonylurea on glucose-stimulated insulin secretion in healthy and non-insulin-dependent diabetic subjects: a dose-response study. Acta Diabetol 28:162-168, 1991
11. Ravanam A, Jeffery J, Nehlawi M, Abraira C: Improvement of glucose-primed intravenous glucose tolerance and correction of acute insulin decrement by glipizide in type II diabetes. Metabolism 40:1173-1177, 1991
12. Bitzen PO, Melander A, Schersten B, Svensson M, Wåhlin-Boll E: Long-term effects of glipizide on insulin secretion and blood glucose control in patients with noninsulin-dependent diabetes mellitus. Eur J Clin Pharmacol 42:77-83, 1992
13. Groop LC: Sulfonylureas in NIDDM. Diabetes Care 15:737-754, 1992
14. Groop P-H, Melander A, Groop LC: The acute effect of preprandial exogenous and endogenous sulfonylurea-stimulated insulin secretion on postprandial glucose excursions in patients with type II diabetes. Diabet Med 10:633-637, 1993
15. Birkeland KI, Furuseth K, Melander A, Mowinckel P, Vaaler S: Long-term randomized placebo-controlled double-blind therapeutic comparison of glipizide and glyburide. Glycemic control and insulin secretion during 15 months. Diabetes Care 17:45-49, 1994
16. Ipp E, Cortez C, Bergner A, Fischette C, Lee W-NP: Glipizide GITS inhibits hepatic glucose production in NIDDM. Program and Abstracts of the 77th Annual Meeting of the Endocrine Society 77:545, 1995
17. Cefalu WT, Bell-Farrow AD, Wang ZQ, McBride DG, Stegner J, Dalgleish DC, Morgan TM, Fischette CF: Insulin sensitivity in vivo is improved after glipizide GITS treatment (Abstract). Diabetes 44 (Suppl. 1):107A, 1995
18. Lebovitz HE, Feinglos MN: Mechanism of action of the second-generation sulfonylurea glipizide. Am J Med 75 (Suppl. 5B):46-54, 1983
19. DeFronzo RA, Simonson DC: Oral sulfonylurea agents suppress hepatic glucose production in non-insulin-dependent diabetic individuals. Diabetes Care 7 (Suppl. 1):72-80, 1984
20. Simonson DC, Ferrannini E, Bevilacqua S, Smith D, Barrett E, Carlson R, DeFronzo RA: Mechanism of improvement in glucose metabolism after chronic glyburide therapy. Diabetes 33:838-845, 1984
21. Groop L, Luzi L, Melander A, Groop P-H, Ratheiser K, Simonson DC, DeFronzo RA: Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects. Diabetes 36:1320-1328, 1987
22. Groop L, Barzilai N, Ratheiser K, Luzi L, Wåhlin-Boll E, Melander A, DeFronzo RA: Dose-dependent effects of glyburide on insulin secretion and glucose uptake in humans. Diabetes Care 14:724-727, 1991
23. Wåhlin-Boll E, Almér L-O, Melander A: Bioavailability, pharmacokinetics and effects of glipizide in type II diabetics. Clin Pharmacokinet 7:363-372, 1982
24. Feldman JM: Glyburide: a second generation sulfonylurea hypoglycemic agent. History, chemistry, metabolism, pharmacokinetics, clinical use, and adverse events. Pharmacotherapy 5:43-62, 1985
25. Jaspan JB: Monitoring and controlling the patient with non-insulin-dependent diabetes mellitus. Metabolism 36 (Suppl. 1):22-27, 1987
26. Drentz AJ, Ferner RE, Bailey CJ: Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 11:223-241, 1994
27. Melander A, Wåhlin-Boll E: Clinical pharmacology of glipizide. Am J Med 75 (Suppl. 5B):41-45, 1983
28. Lebovitz HE: Glipizide: a second generation sulfonylurea hypoglycemic agent. Pharmacology, pharmacokinetics, and clinical use. Pharmacotherapy 5:63-77, 1985
29. Groop L, Wåhlin-Boll E, Groop PH, Totterman KJ, Melander A, Tolppanen EM, Fyhrqvist F: Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type II diabetics. Eur J Clin Pharmacol 28:697-704, 1985
30. Ahren B, Lundquist I, Schersten B: Effects of glipizide on various consecutive insulin secretory stimulations in patients with type II diabetes. Diabetes Res 3:293-300, 1986
31. Melander A: Clinical pharmacology of sulfonylureas. Metabolism 36 (Suppl. 1):12-16, 1987
32. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR: The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 150:1881-1884, 1990
33. Botelho RJ, Dudrak R II: Home assessment of adherence to long-term medication in the elderly. J Fam Pract 35:61-65, 1992
34. Swanson DR, Barclay BL, Wong PSL, Theeuwes F: Nifedipine gastrointestinal therapeutic system. Am J Med 83 (Suppl. 6B):3-9, 1987
35. Emilsson H: High-performance liquid Chromatographic determination of glipizide in human plasma and urine. J Chromatogr 421:319-326, 1987
36. Wåhlin-Boll E, Sartor G, Melander A, Schersten B: Impaired effect of sulfonylurea following increased dosage. Eur J Clin Pharmacol 22:21-25, 1982
37. Stenman S, Melander A, Groop P-H, Groop LC: What is the benefit of increasing the sulfonylurea dose? Ann Intern Med 118:169-172, 1993
38. Groop L, Groop P-H, Stenman S, Saloranta C, Tötterman K-J, Fyhrqvist F, Melander A: Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment. Diabetes Care 10:671-678, 1987
39. Berelowitz M, Fischette C, Cefalu W, Schade DS, Sutfin T, Kourides I: Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM. Diabetes Care 17:1460-1464, 1994
40. Berelowitz M, Go E: Contrasting influences of glipizide GITS on fasting and post-Sustacal Glycemia, glucose production, and 24-h glucose/insulin profiles in NIDDM. Diabetes 45 (Suppl. 2):258A, 1996
41. Tahara Y, Shima K: The response of GHb to stepwise plasma glucose change over time in diabetic patients. Diabetes Care 16:1313-1314, 1993
42. Burge MR, Schmitz K, Tive L, Schade DS: Epinephrine is the mechanism of protection against sulfonylurea-induced hypoglycemia in fasted NIDDM patients. Diabetes 42 (Suppl. 2):61A, 1996
43. Jaber LA, Wenzloff NJ, Komanicky P: An evaluation of the therapeutic effects and dosage equivalence of glyburide and glipizide. J Clin Pharmacol 30:181-188, 1990
44. DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333:541-549, 1995
45. Kradjan WA, Kobayashi KA, Bauer LA, Horn JR, Opheim DE, Wood FJ: Glipizide pharmacokinetics: effects of age, diabetes, and multiple dosing. J Clin Pharmacol 29:1121-1127, 1989
46. Lipson LG, Lipson M: The therapeutic approach to the obese maturity-onset diabetic patient. Arch Intern Med 144:135-138, 1984
47. Lipson LG: Diabetes in the elderly: diagnosis, pathogenesis and therapy. Am J Med 80 (Suppl. 5A):10-21, 1986
48. Wilson PWF, Anderson KM, Kannel WB: Epidemiology of diabetes mellitus in the elderly. Am J Med 80 (Suppl. 5A):3-9, 1986
49. Peters AL, Davidson MB: Use of sulfonylureas in older diabetic patients. Clin Geriatr Med 6:903-921, 1990
50. Rosenstock J, Corrao PJ, Goldberg RB, Kilo C: Diabetes control in the elderly: a randomized, comparative study of glyburide versus glipizide in non-insulin-dependent diabetes mellitus. Clin Ther 15:1031-1040, 1993
51. Rouff G: The management of non-insulin-dependent diabetes mellitus in the elderly. J Fam Pract 36:329-335, 1993
52. Karam JH, Sanz N, Salamon E, Nolte MS: Selective unresponsiveness of pancreatic β-cells to acute sulfonylurea stimulation during sulfonylurea therapy in NIDDM. Diabetes 35:1314-1320, 1986
53. Grunberger G: Maintenance of sulfonylurea responsiveness in NIDDM. Randomized double-blind study of intermittent glyburide therapy Diabetes Care 15:696-699, 1992
54. McIntyre HD, Ma A, Bird DM, Patterson CA, Cameron DP: Chronic sulfonylurea therapy augments basal and meal-stimulated insulin secretion while attenuating insulin responses to sulfonylurea per se. Diabetes Care 15:1534-1540, 1992
55. Widom B, Simonson DC: Iatrogenic hypoglycemia. In Joslin's Diabetes Mellitus. 13th ed. Kahn CR, Weir GC, Eds. Philadelphia, Lea & Febiger, 1994, p. 489-507
56. Burge MR, Schmitz KL, Reinhardt E, Fischette C, Schade DS: Does fasting cause hypoglycemia in elderly NIDDM patients on glipizide GITS or glyburide? (Abstract). Diabetes 44 (Suppl. 1):109A, 1995
57. Riddle M, McDaniel P: Glipizide GITS does not increase the hypoglycemic effect of missing breakfast and mildly exercising (Abstract). Diabetes 44 (Suppl. 1):107A, 1995
58. Brodows RG: Benefits and risks with glyburide and glipizide in elderly NIDDM patients. Diabetes Care 15:75-80, 1992
59. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
60. Ohkubu Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995
61. Klein R, Klein BEK, Moss SE, Cruickshanks KJ: Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Intern Med 154:2169-2178, 1994
62. Kuusisto J, Mykkanen L, Pyorala K, Laakso M: NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 43:960-967, 1994